Proteinsimple

Proteinsimple has been granted 31 US utility patents between 2015 and 2025, placing Proteinsimple at #10,146 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.5 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a US Corporation, Proteinsimple is one of the more focused assignees in the PatentsView dataset. By volume, Proteinsimple sits between Precor Incorporated (31 patents, rank #10,142) and Quantum Metric, Inc. (31 patents, rank #10,150) - the closest US assignees by grant volume. The composite Innovation Score of 52.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 16 grants, compared with 10 in the 2015–2019 window, a +60% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Proteinsimple's 21.5 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 11 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.